NRIX
Nurix Therapeutics, Inc.Company with tickers: NRIX
CIK
1549595
CUSIP
67080M103
Shares Outstanding
103,405,813
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $6,252,000 | USD | 2026-02-28 | 10-Q | 2026-04-08 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $98,747,000 | USD | 2026-02-28 | 10-Q | 2026-04-08 |
| Research & Development | $84,137,000 | USD | 2026-02-28 | 10-Q | 2026-04-08 |
| Operating Income | $-92,495,000 | USD | 2026-02-28 | 10-Q | 2026-04-08 |
| Net Income | $-87,174,000 | USD | 2026-02-28 | 10-Q | 2026-04-08 |
| EPS (Basic) | $-0.79 | USD/shares | 2026-02-28 | 10-Q | 2026-04-08 |
| EPS (Diluted) | $-0.79 | USD/shares | 2026-02-28 | 10-Q | 2026-04-08 |